16 hours Ago By ABMN Staff
D. Boral Capital assumed coverage on shares of AVITA Medical ( NASDAQ:RCEL – Get Free Report ) in a report released on Tuesday, MarketBeat Ratings reports. The firm set a “buy” rating and a $25.
00 price target on the stock. D. Boral Capital’s price objective indicates a potential upside of 93.
65% from the stock’s current price. Separately, Piper Sandler reiterated a “neutral” rating and set a $12.00 price objective (up previously from $9.
00) on shares of AVITA Medical in a research report on Friday, November 8th. Get Our Latest Stock Report on RCEL AVITA Medical Trading Up 9.9 % AVITA Medical ( NASDAQ:RCEL – Get Free Report ) last released its earnings results on Thursday, November 7th.
The company reported ($0.62) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.41) by ($0.
21). The business had revenue of $19.55 million for the quarter, compared to analysts’ expectations of $19.
65 million. AVITA Medical had a negative return on equity of 194.69% and a negative net margin of 95.
47%. During the same quarter in the prior year, the business posted ($0.34) EPS.
On average, sell-side analysts anticipate that AVITA Medical will post -2.35 earnings per share for the current fiscal year. Institutional Investors Weigh In On AVITA Medical A number of hedge funds have recently made changes to their positions in the company.
Rhumbline Advisers grew its holdings in AVITA Medical by 13.9% during the 2nd quarter. Rhumbline Advisers now owns 36,530 shares of the company’s stock valued at $289,000 after buying an additional 4,463 shares in the last quarter.
The Manufacturers Life Insurance Company bought a new position in shares of AVITA Medical during the 2nd quarter valued at approximately $86,000. Essex Investment Management Co. LLC purchased a new position in shares of AVITA Medical in the third quarter valued at $2,477,000.
Huntington National Bank bought a new stake in AVITA Medical in the third quarter worth $32,000. Finally, Quest Partners LLC raised its stake in AVITA Medical by 269.4% during the third quarter.
Quest Partners LLC now owns 7,520 shares of the company’s stock valued at $81,000 after purchasing an additional 5,484 shares in the last quarter. 27.66% of the stock is currently owned by hedge funds and other institutional investors.
AVITA Medical Company Profile ( Get Free Report ) AVITA Medical, Inc, together with its subsidiaries, operates as a regenerative medicine company in the United States and internationally. The company's lead product is the RECELL System, a cell harvesting device used for the treatment of thermal burn wounds, full-thickness skin defects, and repigmentation of stable depigmented vitiligo lesions. Recommended Stories Receive News & Ratings for AVITA Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AVITA Medical and related companies with MarketBeat.
com's FREE daily email newsletter ..
